2,493
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Endometrial cancer with bone marrow metastases: a management dilemma

ORCID Icon, , , , , , & show all
Pages 22-24 | Received 02 Oct 2017, Accepted 17 Oct 2017, Published online: 05 Nov 2017

References

  • Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancer base No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013 [cited 9 2017 Sep]. Available from: http://globocan.iarc.fr
  • Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.10.3322/caac.21208
  • Lajer H, Elnegaard S, Christensen RD, et al. Survival after stage IA endometrial cancer; can follow up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012;91(8):976–82.10.1111/aog.2012.91.issue-8
  • Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(218):e211–216.
  • Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.10.1016/j.ygyno.2003.11.048
  • National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ); 2015. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/healthprofessional
  • Kilickap S, Erman M, Dincer M, et al. Bone marrow metastasis of solid tumors: Clinicopathological evaluation of 73 cases. Turk J Cancer. 2007;37:85–8.
  • Mehdi SR, Bhatt MLB. Metastasis of solid tumors in bone marrow: a study from northern India. Indian J Hematol Blood Transfus. 2011;27(2):93–5.10.1007/s12288-011-0069-z
  • Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol. 1999;17(6):1736–44.10.1200/JCO.1999.17.6.1736
  • Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–78.10.1111/ijg.2007.17.issue-5
  • Thigpen T, Brady MF, Homesley HD et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. JCO; 19:364–7.
  • Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers—a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14(4):650–8.10.1111/ijg.2004.14.issue-4
  • Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000;78(2):212–6.10.1006/gyno.2000.5865
  • Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(3): 771.10.1016/j.ygyno.2012.03.034